Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 August 2019 | Story Zama Feni | Photo Charl Devenish
Innocentia working in the lab
UFS academic, Innocensia Mangoato, doing her work in the laboratory.


Born as the only girl among boys in the Tanzanian capital city of Dar es Salaam in 1992, the University of the Free State (UFS) academic Innocensia Mangoato says she feels inspired by women who strive to break the barricades of patriarchy.

“I am inspired by resilient women who are able to overcome everyday challenges, even in a world that treats men as superiors,” she says.

At the tender age of 27, Mangoato has achieved more than many of her peers. Last year, she won a Women in Science Award (WISA) for her research on the use of cannabis in cancer treatment.  She is now a Doctor of Philosophy (PhD) candidate in Pharmacology and also a researcher and lecturer in the Department of Pharmacology – a job she started in May this year.

Early years

Mangoate’s dad was in exile at the ANC base camp outside Morogoro in Tanzania and met her Tanzanian mother during his stay there; she returned with her parents to South Africa in 1994, as political organisations were already unbanned at that time.

One of the factors that Mangoate attributes her academic success to, is her parents. “Both my parents valued education, and I believe this greatly contributed to my development. Coming from a rural upbringing, one of the lessons I learned is that perseverance and hard work always pay off.”

On her navigation of life – trying to determine what exactly could mould her to become what she wanted to be, Mangoate hailed her father as her pillar of strength. “When the going gets tough, my father has always been there to remind me to “keep on keeping on, no matter how hard it may be, because there’s always victory on the other side.”

Academic success

Mangoate obtained her master’s in Pharmacology at the UFS June 2019 graduation ceremony, one month before South Africa celebrates Women’s Month. She brands herself as “a representative of all women in science” and is enjoying empowering young scientists through lecturing and research at the university.

Asked about what nobody else knows about her, Mangoate hesitated for a moment and then beamed, “I am an academic at heart.” There is no doubt about this, as her academic achievements really attest to that.

On how she envisions the UFS in future, especially with regard to women’s issues, she boldly states: “More women will be running departmental affairs, working towards progressive change within the UFS for both the academics and other programmes.”

She interprets success as something that is measured by happiness, being able to help other people reach their goals, and the ability to achieve all one wishes for, while making sure that it’s both impactful and beneficial to others.

Mangoate’s advice to other would-be academic achievers is that they should be focused and determined when it comes to achieving their goals, working diligently in everything they do, “irrespective of whether you like it or not”.

“Being the only girl among boys has taught me to always strive to be better than myself and not to compete with anyone,” says Mangoate.

“Just show up and give it your all.”

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept